Compare Quest Diagnostics Inc (DGX) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs GameStop Corp. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while GameStop Corp. trades at $26.56 (market cap $12.75B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and GameStop Corp. for 62 Days on average.
| DGX | GME | |
|---|---|---|
Market Cap | $25.48B | $12.75B |
Volume | 941,866 | 13,026,993 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $26.56 |
52-Week Low | $173.49 | $17.87 |
Typical Hold Time | 56 Days | 62 Days |
Enterprise Value | $31.23B | $12.03B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
GME trades at $25.28, up 2.85% today, with a bullish technical signal from moving averages and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, and holds a robust cash position of $4.77 billion. Recent earnings beat expectations in two of the last three quarters, though revenue has declined from $6.0 billion in 2022 to $3.8 billion in 2025.
The outlook is mixed: strong cash reserves and insider confidence support upside, but declining revenue and a high P/E ratio of 16.63 pose risks. Analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution challenges in the retail sector and reliance on insider sentiment rather than fundamental growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
